Hofseth BioCare had operating revenues of MNOK 28,0 in Q4 2013, compared to MNOK 6,4 in Q4 2012. Total operating expenses amounted to MNOK 27,8 in the period (MNOK 25,0). EBITDA amounted to MNOK 0,2 compared to MNOK -18,6 in Q4 2012.
Total assets were MNOK 203,9 at the end of 2013 (MNOK 155,6). Total equity amounted to MNOK 62,0 (MNOK 47,7) giving an equity ratio of 30,4% (30,7%).
Please see HBC's Q4 2013 report attached.
For further information, please contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Tel +47 936 32 966
E-mail: joo@h-bc.no
Øystein Omvik, CFO Hofseth BioCare ASA
Tel: +47 936 99 400
E-mail: oystein.omvik@h-bc.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBCs objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
